Search results
Results From The WOW.Com Content Network
By Sriparna Roy. (Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health ...
(Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and ...
Novartis Gene Therapies, until 2020 known as AveXis, is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in Dallas , Texas , United States in 2012 by John Carbona after reorganizing a company called BioLife Cell Bank founded by David Genecov and John Harkey.
Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). [6] VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
FRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic version of Johnson & Johnson's anti-inflammatory drug Stelara under a collaboration deal with ...
Pelacarsen. Pelacarsen is an antisense therapy that is designed to reduce Lipoprotein (a) concentrations in people with high levels of the lipoprotein and who are at risk of cardiovascular disease. [1] [2] [3] It is developed by Ionis and Novartis. [4]